Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Transgenomic, Amgen in Cancer Detection Pact | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Transgenomic, Amgen in Cancer Detection Pact

Will develop test to screen for mCRC

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Transgenomic, Inc. has entered into a collaboration with Amgen to develop a CE-IVD test to screen patients with metastatic colorectal cancer (mCRC) for RAS mutations (KRAS and NRAS). These RAS mutations are identified with CE-IVD CRC RAScan kits using Surveyor-Wave technology, and provide physicians with important information regarding tumor mutation status. Financial terms were not disclosed.
 
“This collaboration with Amgen is indicative of how Transgenomic’s proprietary molecular technologies are advancing personalized medicine,” said Craig Tuttle, chief executive officer of Transgenomic. “This highly precise, innovative test was developed at Transgenomic’s laboratories, which excel in genomic and genetic analysis, novel technology development, and its application in clinical research and trials.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters